ArticleDiscover nano2026
Evaluation of the efficacy of rutin, rutin nanocrystals, and rutin spanlastics nanoparticles as antitumor and antioxidant drug delivery systems.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoids comprise an exclusive class of biomolecules with extensive therapeutic features. Rutin is one of the flavonoids that has antioxidant, anticancer, and other pharmacological actions, but its clinical use is deterred by poor solubility, poor bioavailability, and incomplete absorption. Development of nanotechnology-based delivery platforms is a promising solution to counter these issues. We evaluated the antioxidant and anticancer properties of nanocrystals and spanlastic nanoparticles of rutin against the human breast adenocarcinoma cell line MCF-7 to establish effective delivery methods with improved therapeutic efficacy. The physicochemical characteristics of the nano-formulations were investigated through particle size and zeta potential measurement, Fourier Transform Infrared spectroscopy (FTIR), transmission electron microscopy (TEM), scanning electron microscopy (SEM), electronic bandgap energy, and dissolution behavior. Antioxidant activity was investigated through DPPH and ABTS radical scavenger assays. Anticancer potential was established through a viability assay, cell cycle analysis, dual labeling with annexin-V/propidium iodide (PI) (using fluorescence-activated flow cytometric methods), and Caspase 3 activity. Rutin spanlastic nanoparticles showed a considerably smaller particle size, homogeneous dispersion, and negative zeta potential, indicating stability. Rutin spanlastic nanoparticles exhibited greater antioxidant activity compared with free rutin and rutin nanocrystals, as manifested through stronger inhibition of the viability of MCF-7 cells, stronger induction of apoptosis (annexin-V/PI double staining and Caspase 3 activity), and significant G1/0 phase cell cycle arrest. These observations imply an increased solubilization and elastovesicular behaviour of spanlastic nanoparticles with enhanced bioactivity of rutin. In conclusion, rutin spanlastic nanoparticles are an efficient delivery vehicle compared to rutin nanocrystals or free rutin in amplifying both antioxidant and anticancer activity, hence warranting further in vivo experiments to treat breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.